Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.

On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking a significant milestone as the first engineered T-cell therapy for solid tumors. Williams delves into the complexities of developing this innovative treatment for synovial sarcoma, a rare and aggressive form of soft-tissue cancer. He also highlights the unique challenges and promising outcomes associated with TCR T-cell therapies, offering a comprehensive understanding of this cutting-edge approach in cancer immunotherapy.

Subscribe to the podcast!
Apple | Spotify | YouTube